The Scientist: Novartis Linked to Retracted Papers?
Novartis Linked to Retracted Papers?
A Japanese newspaper claims that the pharma giant funded flawed research that revealed extra health benefits for one of its top-selling drugs.
April 2, 2013
|for Diovan in a Hong Kong trainWIKIMEDIA, MK2010Novartis may have supported the work of researchers whose favorable studies of one of the company’s best-selling drugs have been retracted, according to a Japanese newspaper. Novartis has distanced itself from the researchers, but the newspaper reported this week that the company had already invested $1 million in their work, a Nature blog reported.
The blood-pressure drug valsartan (Diovan) was the best-selling drug for Novartis’s Japanese subsidiary in 2011, netting $1.3 billion dollars. That boom followed the publication of studies from Hiroaki Matsubara’s group at the Kyoto Prefectural University of Medicine (KPUM) suggesting that valsartin can also reduce the risk of stroke and heart attack—results that made their way into advertisements for the drug, according to Nature.
But in December 2012, two of Matsubara’s papers on Diovan were retracted by the Japanese Circulation Society for “serious errors in data analysis.” Matsubara denied any deliberate wrongdoing and stood by his results, and a university investigation revealed no misconduct. But in February this year, the European Society of Cardiologists retracted another of Matsubara’s Diovan papers, citing “critical problems” with some of the data. Matsubara resigned from the KPUM on February 28, the day before the university started another investigation.
Novartis has attempted to play down its links to the research. When asked about a Novartis scientist who coauthored an earlier study on Diovan with Matsubara’s group but was named on the paper as an affiliate of Osaka University, the company said that its employee “merely gave advice on what type of statistical analysis to use.” But earlier this week, The Mainichi newspaper reported that the company had funded Matsubara’s group to the tune of ¥100 million (around $1 million), according toNature.
-
画像類似の論文#13 (Am J Physiol Heart Circ Physiol. 2009;297:H1673-84.) 8年前
-
画像類似の論文#14 (Am J Physiol Heart Circ Physiol. 2011;300:H154-61.) 8年前
-
画像類似の論文#15 (Hypertension. 2011;58:254-63. ) 8年前
-
画像類似の論文#16 (Kidney Int. 2011 Dec 7. doi: 10.1038/ki.2011.403. [Epub ahead of print]) 8年前
-
画像類似の論文#16 (Kidney Int. 2011 Dec 7. doi: 10.1038/ki.2011.403. [Epub ahead of print]) 8年前
-
画像類似指摘項目#1 8年前
-
画像類似指摘項目#3 8年前
-
画像類似指摘項目#4 8年前
-
画像類似指摘項目#5 8年前
-
画像類似指摘項目#6 8年前
「関連NEWS」カテゴリの最新記事
毎日新聞:降圧剤論文:他の試験にも社員関与 滋賀医大など3大学
フライデー: ドル箱降圧剤の論文撤回「有名教授(京都府立医大)と製薬会社(ノバル...
The Scientist: Novartis Linked to Retracted Papers?
毎日新聞: 降圧剤臨床:スイスの製薬本社、京都の試験で調査開始
朝日新聞:論文撤回問題、製薬会社が専門家調査 ノバルティス
毎日新聞: 降圧剤臨床試験:慈恵医大も調査へ 京都府医大論文問題で
読売新聞: 京都府立医大元教授の降圧剤論文、全て撤回
京都新聞:元教授の3論文撤回 府立医大 臨床研究結果全てに
朝日新聞: 論文撤回さらに3本 京都府医大の元教授
毎日新聞: 京都府立医大:降圧剤の全論文を撤回…松原元教授チーム